This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Unlocking Q4 Potential of Masimo (MASI): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Masimo (MASI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Q4 Earnings Beat Estimates, Sales Miss, Net Margin Rises
by Zacks Equity Research
GEHC's fourth-quarter results reflect strength in the Advanced Visualization Solutions and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
Will BAX's Q4 Earnings Reflect Its Efforts to Counter Headwinds?
by Zacks Equity Research
Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, pharmaceuticals and patient support systems to have driven recovery.
DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.
GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?
by Zacks Equity Research
GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical Services eyes fourth-quarter growth amid pharma stabilization, biologics rebound & contract manufacturing gains. Can WST sustain its momentum?
Ecolab Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Robust segmental performances are likely to have driven ECL's performance in the fourth quarter.
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
by Zacks Equity Research
Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook
by Zacks Equity Research
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
by Zacks Equity Research
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
by Zacks Equity Research
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
by Zacks Equity Research
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?
by Zacks Equity Research
McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
GEHC Stock May Rise With $138M Investment in Cork Facility Expansion
by Zacks Equity Research
GE HealthCare invests $138M to expand its Cork facility to enhance manufacturing capacity for life-saving imaging contrast media and strengthen its global supply chain.
GEHC Stock May Gain on FDA's Nod for the Updated Voluson Expert Series
by Zacks Equity Research
GE HealthCare launches the enhanced Voluson Expert Series to advance women's health with faster, more precise imaging for improved care in obstetrics and gynecology.
Cencora to Report Q1 Earnings: Is a Beat Likely for the Stock?
by Zacks Equity Research
COR's fiscal first-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
by Zacks Equity Research
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.
Labcorp Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
by Zacks Equity Research
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
by Zacks Equity Research
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
TECH Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.